II. Indications
-
HIV Infection (combination therapy)
- NNRTIs carry a high risk of induced HIV resistance
- Never use NNRTIs as monotherapy in HIV Infection
III. Contraindications
- Moderate to severe liver disease (Child-Pugh B or C)
- Avoid in HIV Post Exposure Prophylaxis
IV. Mechanism
- See Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
- First generation NNRTI
V. Medications
- Immediate Release Tablets: 200 mg
- Immediate Release Suspension: 50 mg/5 ml
- Extended Release (XR) Tablets: 100 mg, 400 mg
- Do not chew, crush or split XR tablets
VI. Dosing: Adult
- Use as combination therapy with other Antiretrovirals
- Immediate Release
- Start: 200 mg orally daily for 14 days or until any rash resolves, then
- Next: 200 mg orally twice daily (if NO rash or hepatotoxicity)
- May switch to Nevirapine XR formulation at any time after initial 14 day dose titration
- Restart at daily immediate dose if medication is stopped for >7 days
- Extended Release (Nevirapine XR)
- Take 400 mg orally once daily
-
Renal Dosing
- Give supplemental 200 mg immediate dose after Hemodialysis
VII. Dosing: Child
- Use as combination therapy with other Antiretrovirals
- Immediate Release (age >15 days old)
- Start: 150 mg/m2 (max 200 mg) orally daily for 14 days or until any rash resolves, then
- Next: 150 mg/m2 (max 200 mg) orally twice daily (if NO rash or hepatotoxicity)
- Age 2 to 8 years old may need dose increase to 200 mg/m2 (max 200 mg) twice daily
- May switch to Nevirapine XR formulation at any time after initial 14 day dose titration
- Restart at daily immediate dose if medication is stopped for >7 days
- Extended Release (Nevirapine XR, age >=6 years)
- BSA 0.58 to 0.83 m2: Give 200 mg orally once daily
- BSA 0.84 to 1.16 m2: Give 300 mg orally once daily
- BSA >1.16 m2: Give 400 mg orally once daily (adult dose)
VIII. Adverse Effects
- See NNRTI for class related adverse effects
-
Acute Life-threatening Hypersensitivity Skin Reaction
- Stop Nevirapine and do not rechallenge if signficant drug rash develops
- Rash is less likely if starting at lower daily dose
- Hepatotoxicity
- Severe hepatoxicity risk
- Acute, rapid, severe liver failure has been described after only a few weeks of treatment
- Risk factors
- Pre-treatment CD4 >400 in men or >250 in women
- First 6 weeks of therapy
- Pre-existing liver disease (e.g. Hepatitis B, Hepatitis C or baseline elevated LFTs)
- Contraindicated in moderate to severe liver disease (Child-Pugh B or C)
- Monitoring
- Obtain LFTs at baseline, and at least once montly (as well as 2 weeks after each dose change)
- Monitor LFTs closely for first 18 weeks of treatment
- Stop Nevirapine and do not rechallenge if signficant hepatotoxicity occurs
- Severe hepatoxicity risk
IX. Safety
X. Drug Interactions
-
Granulocytopenia
- More common in children coadministered Zidovudine
-
CYP3A4 Inducer
- Avoid with Atazanavir, Ketoconazole, Oral Contraceptives or St Johns Wort
-
Methadone
- Nevirapine may reduce Methadone effects
XI. Efficacy
- Original studies showed good efficacy when combined with 2 Nucleoside Reverse Transcriptase Inhibitors (nRTIs)
XII. Resources
- Nevirapine Immediate Release Suspension or Tablet (DailyMed)
- Nevirapine Extended Release (DailyMed)
XIII. References
Images: Related links to external sites (from Bing)
Related Studies
Definition (NCI) | A benzodiazepine non-nucleoside reverse transcriptase inhibitor. In combination with other antiretroviral drugs, nevirapine reduces HIV viral loads and increases CD4 counts, thereby retarding or preventing the damage to the immune system and reducing the risk of developing AIDS. |
Definition (MSH) | A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS. |
Definition (CSP) | potent, non-nucleoside reverse transcriptase inhibitor used, usually in combination with nucleoside analogs, for treatment of HIV infection and AIDS. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D019829 |
SnomedCT | 108704001, 386898005 |
LNC | LP21317-0, MTHU013861 |
English | 6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-, Nevirapine, nevirapine, nevirapine (medication), Nevirapine [Chemical/Ingredient], NEVIRAPINE, 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, NVP, Nevirapine (product), Nevirapine (substance) |
Swedish | Nevirapin |
Czech | nevirapin |
Finnish | Nevirapiini |
Russian | NEVIRAPIN, НЕВИРАПИН |
Japanese | ネビラピン |
Polish | Newirapina |
Spanish | nevirapina (producto), nevirapina (sustancia), nevirapina, Nevirapina |
French | Névirapine |
German | Nevirapin |
Italian | Nevirapina |
Portuguese | Nevirapina |
Ontology: Viramune (C0728726)
Concepts | Pharmacologic Substance (T121) , Nucleic Acid, Nucleoside, or Nucleotide (T114) |
MSH | D019829 |
English | viramune, Viramune |